Scientific output 2005-2010

ARTICLES

1.          S. Heuking, B. Rothen-Rutishauser, P. Gehr and G. Borchard, Fate of TLR-2 agonist functionalized pDNA nanocarriers upon deposition at the bronchial epithelium in vitro. (2010) submitted. 

2.          C. Mueller, M.A.H. Capelle, T. Arvinte, E. Seyrek and G. Borchard, Tryptophan-mPEGs: Novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation. (2010) submitted.  

3.          S. Heuking and G. Borchard, Functionalization with a TLR-7 agonist enhances the immunogenicity of chitosan DNA nanoparticles in human THP-1 macrophages. (2010) submitted. 

4.          F. Lebre, G. Borchard, M.C. Pedroso de Lima and O. Borges, Progress towards a needle-free hepatitis B vaccine. (2010) submitted. 

5.          L. Neutsch, V. Plattner, S. Polster-Wildhofen, A. Zidar, A. Chott, G. Borchard, O. Zechner, F. Gabor and M. Wirth, Lectin-mediated biorecognition as a novel strategy for targeted delivery to bladder cancer. (2010) submitted.  

6.          C. Mueller, M.A.H. Capelle, T. Arvinte, E. Seyrek and G. Borchard, Non-covalent PEGylation as a new means against aggregation of salmon calcitonin. J. Pharm. Sci. (2010) accepted for publication. 

7.          G. Borchard, Nanomedicine and immunotherapy (invited editorial). Expert Rev. Vaccines (2010), accepted for publication. 

8.          A. Misra, A.J. Hickey, B. Fourie, C. Rossi, G. Borchard, H. Terada, K. Makino and P. Colombo. inhaled drug therapy for treatment of tuberculosis. Tuberculosis (2010) doi:10.1016/j.tube.2010.08.009.

9.          F. Esmaeili, S. Heuking, H.E. Junginger and G. Borchard, Chitosan and vaccines. J. Drug Deliv. Sci. Technol. 20 (2010) 53-61.

10.       O. Borges, F. Lebre, D. Bento, G. Borchard and H.E. Junginger, Mucosal vaccines: recent progress in understanding the natural barriers. Pharm. Res. 27 (2010) 211-223.

2009

11.       S. Heuking, A. Iannitelli, A. di Stefano and G. Borchard, Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination. Int. J. Pharm. 381 (2009) 97-105.

12.       S. Heuking, S. Adam-Malpel, E. Sublet, A. Iannitelli, A. di Stefano and G. Borchard, Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. J. Drug Target. 17 (2009) 662 - 670.

13.       M. Bivas-Benita, M.-Y. Lin, S. Bal, K.E. van Meijgaarden, K.L.M.C. Franken, A.H. Friggen, H.E. Junginger, G. Borchard, M.R. Klein and T.H.M. Ottenhoff, Pulmonary vaccination with DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 27 (2009) 4010-4017.

14.       M. Troccaz, C. Vuilleumier, S. Raviot-Derrien, G. Borchard and C. Starkenmann, Gender-specific differences between the concentrations of nonvolatile (R)/(S)-3-methyl-3-sulfanylhexan-1-ol and (R)/(S)-3-hydroxy-3-methyl-hexanoic acid odor precursors in axillary secretions. Chem. Senses 34 (2009) 203-210.

2008

15.       M. Troccaz, F. Benattia, G. Borchard and A.J. Clark, Properties of recombinant Staphylococcus haemolyticus cystathionine ß -lyase (met C) and its potential role in the generation of volatile thiols in axillary malodour. Chemistry and Biodiversity 5 (2008) 2372-2385.

16.       O. Borges, M. Silva, A. de Sousa, G. Borchard, H.E. Junginger and A. Cordeiro da Silva, Alginate coated nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int. Immunopharmacol. 8 (2008) 1773-1780.

17.       O. Borges, A. Cordeiro da Silva, J. Tavares, N. Santarém, A. de Sousa, G. Borchard and H.E. Junginger, Immune response by nasal delivery of hepatitis B surface antigen and co-delivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur. J. Pharm. Biopharm. 69 (2008) 405-416.

2007

18.       O. Borges, J. Tavares, A. de Sousa, G. Borchard, H.E. Junginger and A. Cordeiro-da–Silva, Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate coated chitosan nanoparticles. Eur. J.  Pharm. Sci. 32 (2007) 278-290. 

19.       O. Borges, G. Borchard, A. de Sousa, H.E. Junginger and A. Cordeiro da Silva, Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers. Int. J. Pharm. 337 (2007) 254-264.

20.       H. Zhao, P. Peng, C. Longley, Y. Zhang, V. Borowski, M. Mehlig, P. Reddy, J. Xia, G. Borchard, J. Lipman, L. Benimetskaya and C.A. Stein, Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic and anti-tumor efficacy. J. Control. Rel. 119 (2007) 143-152.

2006

21.       O. Borges, A.C. da Silva, G. Borchard, S.G. Romeijn, M. Amidi, A. de Sousa and H.E. Junginger, Uptake studies in rat Peyer’s patches, cytotoxicity and release studies of alginate-coated chitosan nanoparticles for mucosal vaccination. J. Control. Rel. 114 (2006) 348-358.

22.       M. Amidi, S.G. Romeijn, G. Borchard, H.E. Junginger, W.E. Hennink, W. Jiskoot, Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J. Control. Rel. 111 (2006) 107-116.

23.       B.I. Florea, M. Thanou, H.E. Junginger and G. Borchard, Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. J. Control. Rel.  110 (2006) 353-361.

24.       Y. Pérez de Diego, H.C. Pellikaan, F.E. Wubbolts, G. Borchard, G.J. Witkamp and P.J. Jansens, Opening new operating windows for polymer and protein micronisation using the PCA process. J. Supercrit. Fluids 36 (2006) 216-224.

2005

25.       D. Yu, P. Peng, S.S. Dharap, Y. Wang, M. Mehlig, P. Chandna, H. Zhao, D. Filpula, K. Yang, V. Borowski, G. Borchard, Z. Zhang and T. Minko, Antitumor activity of poly(ethylene glycol)–camptothecin conjugate: The inhibition of tumor growth in vivo. J. Control. Rel. 110 (2005) 90-102.

26.       O. Borges, G. Borchard, J.C. Verhoef, A. de Sousa and H.E. Junginger, Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int. J. Pharm. 299 (2005) 155-166.

27.       M. Bivas-Benita, T.H.M. Ottenhoff, H.E. Junginger and G. Borchard, Pulmonary DNA vaccination: Concepts, possibilities and perspectives. J. Control. Rel. 107 (2005) 1-29.

28.       M. Bivas-Benita, R. Zwier, H.E. Junginger and G. Borchard, Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur. J. Pharm. Biopharm. 61 (2005) 214-218.

 

BOOKS 

1.     G. Borchard, H.L. Lueßen, H.-C. Mahler, Protein Pharmaceuticals - Formulation, Analytics and Delivery. Editio Cantor Verlag, Aulendorf, Germany (2009). 

 BOOK CHAPTERS

1.     G. Borchard, Chitosan-based delivery systems for mucosal vaccination, in: B. Sarmento, J. das Neves (eds.), Chitosan-based systems for biopharmaceuticals: Delivery, targeting and polymer therapeutics, John Wiley & Sons (2011), in preparation.

2.     S. Heuking and G. Borchard, pulmonary gene delivery, CRS (2010), in preparation.

3.     G. Borchard, Parenteral verabreichte Proteintherapeutika, in: C. Mäder, Weidenauer (eds.), Innovative Arzneiformen, Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany (2009) 221-234.

4.     G. Borchard, Intestinal absorption barrier, in: A. Bernkopp-Schnürch (ed.), Oral delivery of macromolecular drugs: Barriers, Strategies and Future Trends, Springer Verlag (2009) 49-64.

5.     C. Müller and G. Borchard, PEGylation and drug modifying techniques for sustained drug action, in: G. Borchard, H.L. Lueßen and H.C. Mahler (eds.), Protein Pharmaceuticals – Formulation, Analytics and Delivery, Editio Cantor Verlag, Aulendorf, Germany (2009) 312-353.

6.     G. Borchard, A changing paradigm: Pulmonary delivery of vaccines for mucosal immunization, in: K. Bechtold-Peters and H.L. Lueßen (eds.), Pulmonary Drug Delivery, Editio Cantor Verlag, Aulendorf, Germany (2007), 354-371.

 

OTHER PUBLICATIONS:

 1.     H.L. Luessen and G. Borchard, Protein Pharmaceuticals - Recent achievements and trends for formulation and delivery. Editorial, OnDrug Delivery, May 2010.

 2.     G. Borchard, PEGylation: Quo Vadis? APV Focus Group Drug Delivery Newsletter, Issue 3, 2006, 4-8. 


PATENTS/APPLICATIONS

  1. G. Borchard, C. Müller, T. Arvinte, M. Capelle. Stabilized protein formulations and use thereof. US61257054, November 2, 2009.

  2. Y.N. Kalia, A. Naik and N. Abla. Topical drug delivery by iontophoresis. PCT application Aug. 2006.
  3. A. Sharma, S.R. Patel, V.N.R.K. Reddy, P. Keusch, Y.N. Kalia. Gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch. US patent application 2006.

INVITED PRESENTATIONS 

1.          Mission insoluble: turning bricks into therapeutics. 25ème séminaire de 3ème cycle en sciences pharmaceutiques, Zermatt, Switzerland, September 2010.

2.          Delivery of biopharmaceuticals. Capsulution Pharma AG, Berlin, Germany, May 2010.

3.          How to write a world-class paper. Interactive Author Workshop, Český svaz vědeckotechnických společností (CSVTS), Prague, Czech Republic, April 2010. 

4.          Pulmonary vaccine delivery. Biological Barriers 2010, University of the Saarland, Saarbrücken, Germany, March 2010.

5.          S. Heuking and G. Borchard, TLR-ligand functionalized nanocarrier systems for mucosal vaccination. World Meeting of Pharmaceutical Technology, Valletta, Malta, March 2010

6.          The future of macromolecular drug delivery - A very personal view. 12th Conference on Formulation and Delivery of Bioactives, Dunedin, New Zealand, February 2010.

2009

7.          Mucosal vaccination using TLR-ligand functionalized nanocarrier systems. University of Bern, institute of Anatomy, Bern, Switzerland, December 2009.

8.          Mucosal DNA vaccination for tuberculosis? Symposium on the optimization of inhaled tuberculosis therapies and implications for host-pathogen interactions, New Delhi, India, November 2009.

9.          TLR-ligand decorated nanoparticles for mucosal vaccination. 2nd Symposium on Novel drug Delivery Systems, University of Salerno, Italy, October 2009

10.       TLR-Liganden dekorierte Nanopartikel für die mukosale Vakzinierung. Annual Meeting of the German Society of Pharmaceutical Sciences (DPhG), University of Jena, Germany, September 2009.

11.       Do as the virus do: Advances in vaccine delivery systems. 14th European Congress on Biotechnology, European Federation of Biotechnology (EFB), Barcelona, Spain, September 2009.

12.       Targeting of TLR ligand nanocarriers to human macrophages. University of Vienna, Austria, June 2009.

13.       Mucosal vaccination. ALK Pharma, Copenhague, Denmark, May 2009.

14.       Librairie = Liberté? Can professional data mining support academic research? Library Connect Forum, Berlin, Germany, May 2009. 

2008

15.       Pulmonary vaccination: opportunities and challenges. Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS), Atlanta, GA, November 2008. 

16.       Vaccination using aerosols. XIII. Deutsches Aerosol Therapie Seminar, Marburg, Germany, November 2008. 

17.       Mucosal immunization using DNA vaccines. Science to Market conference, European Association of Pharma Biotechnology (EAPB), Hannover, Germany, October 2008. 

18.       Exubera, biosimilars et al.: Development of biopharmaceuticals. First Swiss Pharma Science Day, University of Berne, Switzerland, October 2008. 

19.       Improving the PK/PD properties of biopharmaceuticals. Bio Production Forum - Finished Product Manufacturing, Schaffhausen, Switzerland, September 2008.

20.       Gone viral - Enhancing effectiveness of vaccine delivery systems. IPTS meeting, Antalya, Turkey, September 2008. 

21.       Is there a need for nanotechnology in immunotherapy? 7th Central European Symposium on Pharmaceutical Technology and Biodelivery Systems, Ljubljana, Slovenia, September 2008. 

22.       Alternate routes for vaccine administration. World Congress of Pharmacy and Pharmaceutical Sciences, Fédération Internationale de Pharmacie (FIP), Basel, Switzerland, September 2008.

23.       New aspects in vaccine delivery. Iranian Pharmaceutical Sciences Conference (IPSC) 2008, Kerman, Iran, August 2008. 

24.       Challenges and opportunities in mucosal vaccination. GlaxoSmithKline (GSK) lecture, University of Montréal, Montréal, Canada, June 2008. 

25.       Exubera, C.E.R.A., biosimilars - delivery of biopharmaceuticals reviewed. CRS Local Chapter Germany, University of Braunschweig, Germany, March 2008. 

26.       Pulmonary vaccination against tuberculosis. Seminar, University of Padova, Italy, February 2008. 

27.       Management Training: Scientific Writing, Interactive Author Master Class, 7th Conference and Workshop on Biological barriers and nanomedicine, Saarbrücken University, Saarbrücken, Germany, February 2008. 

28.       Of cab drivers and kitchen maids. Symposium at the University of Frankfurt, Frankfurt, Germany, February 2008.

29.       Do we need to pay the Toll? Novel delivery systems for pulmonary vaccination. University of Singapore, Singapore, January 2008.

2007 

30.       Between academia and industry: Pharmaceutical Sciences from an international perspective. APV Meeting, University of Munich, Germany, December 2007.

31.       Modification of protein drugs – PEGylation revisited. Seminar, University of Munich, Germany, December 2007.

32.       Development of novel delivery systems for pulmonary DNA vaccination against tuberculosis. 1st Indo-Japanese International Joint Symposium on Overcoming Intractable Infectious Diseases, Tokyo, Japan, November 2007. 

33.       Novel materials for mucosal pulmonary vaccination. University of Chieti, Italy, September 2007.

34.       Materials for mucosal vaccine delivery: Exploiting the Toll-like receptor activation pathway. IPORSIP Conference, Istanbul, Turkey, September 2007. 

35.       Delivery of macromolecular drugs by the pulmonary route. Novartis Pharma AG, Basel, Switzerland, September 2007. 

36.       Materials for mucosal vaccination. Saarland University, Saarbrücken, Germany, May 2007.

37.       Targeting Toll: new materials for mucosal vaccination. University of Coimbra, Portugal, May 2007. 

38.       Between academia and industry: Pharmaceutical Sciences from an international perspective. APV Meeting, University of Tübingen, Germany, April 2007.

39.       Biopharmaceutical and pharmacokinetic properties of biotech drugs. University of Lyon, France, April 2007.

40.       Pulmonary application of vaccines. Naresuan University, Phitsanulok, Thailand, January 2007. 

2006

41.       In vitro models for pulmonary drug absorption. APV course Trends in Pulmonary Delivery, Marburg, Germany, November 2006.

42.       Pharmaceutics and Biopharmaceutics at the School of Pharmacy Geneva-Lausanne. Arc Alpin Meeting, Archamps, France, November 2006.

43.       Mucosal vaccination using particulate delivery systems. Global Pharmaceutical Education Network (GPEN), University of Kansas, Lawrence, KS, USA, October 2006.

44.       Severe combined immunodeficiency (SCID): Enzyme replacement and gene therapy. 21me Séminaire en Sciences Pharmaceutiques, Zermatt, Switzerland, October 2006

45.       Advanced formulation and drug delivery strategies for interferon-beta. RNF investigator meeting, London, UK, September 2006.

46.       Modification of recombinant proteins by PEGylation. APV course APIs derived from microorganisms, Vienna, Austria, September 2006.

47.       PEGylation of proteins. Merckle Biotech, Ulm, Germany, August 2006.

48.       Biosimilars or Not-So-Similars: The European perspective. Lactrims 2006, Isla Margerita, Venezuela, June 2006.

49.       The bronchial epithelium – more than just a barrier. ETH Zurich, Zurich, Switzerland, June 2006.

50.       La science biopharmaceutique en gros et en détails. L’université de troisième âge, Geneva, Switzerland, April 2006.

51.       Stabilization and delivery of therapeutic antisense oligonucleotides. Antisense Pharma, Regensburg, Germany, April 2006.

52.       Centre Pharmapeptdies: Studies in molecular biopharmaceutics and cellular pharmacokinetics. Merck, Darmstadt, Germany, April 2006.

53.       Polymeric systems for the delivery of biopharmaceuticals. Nestlé Research Center, Lausanne, Switzerland, March 2006.

54.       PEG modification of macromolecular drugs: A tool for improving pharmacokinetics and therapeutic activity. Firmenich, Geneva, Switzerland, February 2006.

55.       Protein formulation and delivery. Serono, Aubonne, Switzerland, February 2006.

56.       Improving delivery of current disease-modifying drugs. Foundation Serono Symposia International, Rome, Italy, January 2006.

2005 

57.       Reversible PEGylation of antisense oligonucleotides. 11. Rencontre Pharmapeptides, Archamps, France, December 2005.

58.       Pegasys, Macugen & Co.: Wie lassen sich die biopharmazeutischen und pharmakokinetischen Eigenschaften von großmolekularen Arzneistoffen verbessern? DPhG Saarland, University of Saarbrücken, Germany, December 2005.  

59.       Pulmonary delivery of active and passive vaccines. Annual AAPS meeting 2005, Nashville, TN, November 2005.

60.       Improvement of protein drug delivery by macromolecular engineering. 6th International Symposium on Advances in Technology and Business Potential of New Drug Delivery Systems, Mumbai, India, February 2005.